Recent Quotes (30 days)

You have no recent quotes
chg | %

International Technology Systems Inc.  

(Public, OTCMKTS:IMMB)   Watch this stock  
Find more results forPINK:IMMB
0.0000 (0.00%)
Jul 15 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.03
Open     -
Vol / Avg. 0.00/5,443.00
Mkt cap 533,460.00
P/E     -
Div/yield     -
EPS -221.70
Shares 60.56M
Beta -3.66
Inst. own     -

Key stats and ratios

Q3 (Sep '06) 2005
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -187.88% -134384.00%
Return on average equity - -
Employees 4 -
CDP Score - -


120 W Pomona ave
United States - Map
+1-818-4212090 (Phone)
+1-818-4098988 (Fax)

Website links


Immunotech Laboratories, Inc. (Immunotech), is a development-stage company. Immunotech is engaged in the medical research and development of protein-based therapeutic and diagnostic products with applications in human immunodeficiency virus/ acquired immune deficiency syndrome (HIV/AIDS). The Company’s two products include Irreversible Pepsin Fraction (IPF) and Immune Therapeutic Vaccine-1 (ITV-1). The IPF peptide molecule is used for the treatment and prevention of the HIV/AIDS indication. The Company is focused on the commercialization of its proteins for the treatment of debilitating infectious diseases. Immunotech’s other compounds in its pipeline include pediatric HIV/AIDS treatment (ITV-2), pre-natal HIV/AIDS treatment (ITV-3) and preventive HIV/AIDS Vaccine (ITV-4).

Officers and directors

Harry H. Zhabilov Vice Chairman of the Board, Chief Science Officer
Age: 44
Roscoe M. Moore Jr., Ph.D. Director